Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. MarketScreener: Created by Investors for Investors! Michael earned a DVM at the University of Pretoria and a PhD in Immunology at the University of Pennsylvania. Prithviraj has a BS from Duke University and an MBA from Kellogg School of Management, Northwestern University. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Before pursuing an M.B.A. at Harvard Business School, Michael received his M.D. Katherine Terranova is an Associate within the TechAtlas division of RA Capital Management. Shannon has a BA in Special Education and English from Bridgewater University and a MS in Elementary Education from Boston College. Shannon's primary responsibilities are to manage the front desk and office facilities. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia. Drew Biedermann is an Associate with the TechAtlas division of RA Capital Management. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. View Profile. Parents need to know that Peter Pan & Wendy takes on some of the weightier themes of J.M. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. Ed has 30 years of experience in preclinical and clinical drug development, and in regulatory affairs for pharmaceutical and biotechnology companies. Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Tom is a Senior Operations Analyst at RA Capital Management. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Prior to IGEN Cony worked for Corning in the US and in Europe. Dan studied Network Communications & Information Services at Lincoln Technical. Brian's primary responsibility at RA Capital is to manage the firm's IT Operations needs. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Mike earned his MBA from the Darden Graduate School of Business Administration. RA Capital | Team Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. A funny, joyous romance on the streets of south London, plus Jude Law is a menacing Captain Hook in the new Neverland coming-of-age adventure Simon Wardell Fri 28 Apr 2023 04.00 EDT Samuel Chowdhury is a Software Engineerat RA Capital Management. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. Megan has a BS in Microbiology & Cell Science from University of Florida. He also provided additional system administration and training for the desktop engineering team. Prior to this role, Anurag was at Orbimed Advisors where he served as Vice President, Structured Growth Capital and Royalty Opportunities. in Anthropology and Natural Sciences and an M.S. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Abhishek is a Data Analyst Associate at RA Capital Management. Peter Kolchinsky - Biography - MarketScreener.com Ross Chikarmane is an Associate with the TechAtlas division of RA Capital Management. Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Prior to that, he was a Life Sciences Investment Associate at Brigham Capital. Prior to her stint coaching, she received her BS in Psychology with a Minor in History from Union College in NY. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Kathryn Meng is an Investment Director within the Planetary Health division of RA Capital. Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. RA Capital and CEO of Arcuate Therapeutics. Prior to RAVen, Scott was President and Managing Director of The Branta Group LLC, a healthcare company formation, capital investment, and strategic advisory firm known for taking an active management role with its clients and portfolio companies in the biotechnology, medical device, diagnostics, venture capital, and private equity sectors. He is active in both public and private investments In biotechnology areas as diverse as drugs, medical devices, diagnostics, and life science tools. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. In this role, he gained broad expertise across all phases of drug discovery, early development, and clinical research. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. James was a post-doctoral fellow at Massachusetts Institute of Technology and University of California, Berkeley. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Christinas primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Alex is an Associate with the TechAtlas division of RA Capital Management. Joe DeMaio is IT Operations Associate at RA Capital Management. Prior to Point32Health, Michael served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania. Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA. Angela also gained experience in prior roles as Clinical Trial Manager at Roche, Sarepta, and other companies, and Clinical Research Coordinator at Tufts Medical Center and Dana-Farber Cancer Institute. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. Kat has a BS in Business Administration, majoring in Accounting from the University of Minnesota, Carlson School of Management. Soumya has contributed to over 75 drug discovery programs ranging from small startups to large pharma, leading to nine development candidates currently in various stages of clinical trials. So it's not patents holding back production. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . He worked previously as a Patient Coordinator at Massachusetts General Hospital. She was also an Entrepreneurial Fellow at VentureLabs for Flagship Pioneering. Her graduate research investigated synaptic translation in syndromic autism. Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis. Monica Stanciu is an Associate Director within the TechAtlas division at RA Capital Management. He holds a BS in Computer Science from Northeastern University. Cristina Ghenoiu is a Principal on the Venture Team at RA Capital Management. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Prior to joining RA, Michael was Associate Vice President at Merck Research Labs. Prior to RAVen, he was a member of the founding team and Chief Operating Officer at Catamaran Bio, a CAR-NK cell therapy company. Andrew is a Software Developer at RA Capital Management. Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. Rebecca conducts due diligence on biotechnology companies at RA Capital. January 3, 2023 Feb 10th, Ed. Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. Her primary responsibilities are to assist with all finance operations related to the Firm. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Prior to Mintz, Kate held a Paralegal role at Loughran & Corbett, Attorneys, Inc. Kate holds a Bachelor's Degree in Political Science from Bridgewater State University and is a certified Paralegal in Massachusetts. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. Previously, Neil was Director, Business Development and Project Management at CiVentiChem (acquired by Sterling Pharma Solutions). Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. Prior to MP, she was a Consultant at Clarion Healthcare. He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. Special Projects Operations Manager/Chief of Staff. Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. Soumya completed his postdoc at Brigham and Womens Hospital and held an Assistant Professor of Neuroscience role at Harvard Medical School Neurology Department where he contributed to the Harvard Neurodiscovery Centers (HNDC) academic drug discovery initiative as a modeler and drug hunter. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. He holds Microsoft 365 and Microsoft certifications as Messaging Administrator Associate, Teams Administrator Associate, Teamwork Administrator Associate, and Azure Administrator Associate. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Before Energetic, she was Head of Carbon Strategic Partnerships at Indigo Ag, where she led external innovation focused on solutions that minimize or sequester agricultural GHG emissions and deliver additional environmental, social, and economic co-benefits. Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Kritis primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Adison is an Executive Assistant RA Capital Management. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Raj holds a BA from Cornell University, where he majored in Chemistry. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. 239 Kelton St, Allston, MA . Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Prior to founding The Branta Group LLC in 2003, he was a co-founder and Chief Business Officer of Orchid GeneShield, a subsidiary of Orchid BioSciences (Nasdaq: ORCH), which was formed after he acquired a healthcare informatics company and merged it with Orchids pharmacogenetics business to create innovative personalized consumer healthcare products in partnership with leading healthcare companies. Alex comes to RA from Mirai Advisory, where he specialized in financial risk and data science and developed machine learning algorithms to support banks managing regulatory and operational challenges. Rebecca Silberman is an Analyst on the Venture Team at RA Capital Management. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. Semper Maior: Time to Reboot Biotech RApport Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Jeff Breay is a Head Trader at RA Capital Management. Jeff holds a BA in Economics and Psychology from Georgetown. Previously, Gunes worked closely with the Investment Team, as a Senior Associate within RAs TechAtlas division. Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. She works with RAs newcos to develop optimal pitch decks and public messaging, authors articles, and runs the firms internal and external business courses. His research investigated chromatin structure and transcription factor binding. Kate McKenna is a Compliance Associate at RA Capital Management. Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). Emilys primary responsibility at RA Capital isdesigning and overseeing the brand management for RA Capital's internal and external communications as well assisting with the brand identity forportfolio companiesfounded through RA Capital's incubator, RA Ventures. in Biomedical Anthropology from the University of Pennsylvania. Peter Kolchinsky, Ph.D. In his career, Scott has worked to raise over $600 million in funding for ventures with which he has been directly involved as a founder or operating executive. She holds a BBA in Marketing from Loyola University Maryland. Previously, Nate covered atopic dermatitis, psoriasis, dermatology, colorectal cancer, cancer diagnostics, and broader tools and diagnostics as a Senior Associate within RAs TechAtlas division.